Lymphoma symptoms often start quietly: a lump in the neck that does not hurt, a run of drenching night sweats, or a tiredness that rest does not fix. Because those same signs follow ordinary infections, most people who notice them do not have cancer. A swelling that keeps going for several weeks, however, deserves a proper look. Lymphoma is a cancer of the lymphatic system, the network of vessels, nodes and organs that moves immune cells around the body. In this article you’ll learn which signs actually matter, how Hodgkin and non-Hodgkin lymphoma differ, what blood tests can and cannot tell you, why a lymph node biopsy is the only test that confirms the diagnosis, and how treatment has changed with CAR-T cell therapy and bispecific antibodies.
What lymphoma is and where it begins
Lymphoma begins in lymphocytes, the white blood cells that patrol the body looking for infection. They travel through the lymphatic system, a second circulation running alongside the blood vessels, dotted with hundreds of small filtering stations called lymph nodes — clustered in the neck, armpits, chest, abdomen and groin. The spleen, thymus, tonsils and bone marrow belong to the same system.
In lymphoma, one lymphocyte acquires genetic changes that let it divide without stopping and ignore the normal signal to die. Its descendants pile up inside nodes and lymphatic tissue, which is why a painless, growing lump is the classic first of the lymphoma symptoms people notice. Because lymphatic tissue exists nearly everywhere, the disease can also start in the stomach, skin, brain, bone or thyroid.
Hodgkin and non-Hodgkin lymphoma side by side
Pathologists recognize more than seventy subtypes, grouped into two families, and the distinction shapes staging, treatment intensity and outlook. Hodgkin lymphoma is defined by a particular abnormal cell visible under the microscope; everything else falls under non-Hodgkin lymphoma.
| Feature | Hodgkin lymphoma | Non-Hodgkin lymphoma |
|---|---|---|
| Share of cases | Roughly one in ten lymphomas | The large majority |
| Defining cell | Reed-Sternberg cell seen on biopsy | Many different B-cell or T-cell patterns |
| Typical age | Two peaks: young adults, then after 55 | Risk climbs steadily with age |
| How it spreads | Usually node group to neighboring node group | Often scattered, and more often outside nodes |
| Pace | Generally fast-growing but highly treatable | Ranges from very slow to very aggressive |
| Usual first treatment | Combination chemotherapy, sometimes radiation | Depends entirely on subtype and pace |
Lymphoma symptoms and what they actually feel like
No single sign points to lymphoma on its own. What raises a clinician’s attention is a pattern, because lymphoma symptoms tend to arrive together: a swelling that does not settle, combined with body-wide signs that have no obvious explanation.
Swollen lymph nodes, the most common first sign
The lump people notice first is usually a lymph node in the neck, above the collarbone, in the armpit or in the groin. Compared with the tender, mobile nodes of a throat infection, a node involved by lymphoma is more often painless, firm or rubbery, slow to shrink, and gradually enlarging over weeks rather than days. Size alone proves nothing: plenty of people carry small, permanently palpable nodes from old infections.
The three systemic signs doctors call B symptoms
Three body-wide features carry particular weight because they signal that the whole system is affected, not one node. Clinicians group them as B symptoms:
- Fever above 100.4 degrees Fahrenheit with no infection found, often coming and going over weeks.
- Night sweats heavy enough to soak sleepwear or bedding, not simply feeling warm.
- Unintentional weight loss of more than a tenth of body weight over six months.
Persistent itching without a rash, node pain after drinking alcohol, and fatigue that sleep does not lift are also reported, particularly in Hodgkin lymphoma.
Symptoms that depend on location
Because lymphatic tissue is everywhere, lymphoma symptoms vary with where the disease has settled. Nodes in the chest can press on the airway and cause a dry cough, breathlessness or pressure behind the breastbone. Disease in the abdomen may bring early fullness after small meals, bloating or belly pain, and an enlarged spleen creates discomfort under the left ribs. Lymphoma in the bone marrow crowds out normal blood production, which is why some people arrive pale and short of breath, bruising easily or catching repeated infections.
When to see a doctor about a swollen lymph node
Most swollen nodes are reactive: they grow because the immune system is doing its job, then settle within two to three weeks. A 2024 review of lymphadenopathy of unknown origin proposed a simple rule for adults — any node still abnormal beyond two weeks should be treated as suspicious and investigated, rather than watched indefinitely.
Book an appointment without waiting if you notice any of the following:
- A lump present for more than two to three weeks that is not shrinking.
- A node that is painless, hard or fixed rather than sliding under the finger.
- A node larger than roughly an inch across, or clearly still growing.
- Swelling just above the collarbone, which warrants prompt assessment at any size.
- Node swelling combined with fever, drenching night sweats or unexplained weight loss.
- Several separate node areas enlarging at once.
Seek same-day care for breathlessness, facial or neck swelling with visible vein distension, or severe abdominal pain, which can reflect a mass pressing on major structures.
Causes and risk factors
Lymphoma is not contagious, is not inherited in a straightforward way, and in most people no cause is ever found. Nothing you did brought on your lymphoma symptoms. Research has identified conditions that shift the odds slightly, usually by keeping lymphocytes under long-term stimulation or weakening immune surveillance.
- Age, with risk rising across adult life for most non-Hodgkin subtypes.
- A weakened immune system, from transplant medication, inherited immune deficiency, or an infection that damages immune defenses. Workups here often include HIV testing.
- Certain infections, notably Epstein-Barr virus — the virus that also causes mononucleosis — along with Helicobacter pylori in the stomach and hepatitis C.
- Long-standing autoimmune disease such as rheumatoid arthritis, lupus or celiac disease.
- Occupational exposure to some pesticides and industrial solvents.
- Previous chemotherapy or radiation for another cancer.
- A first-degree relative with lymphoma, which raises relative risk modestly while absolute risk stays low.
Having one or several of these does not mean lymphoma will develop. The National Cancer Institute’s patient overview of lymphoma makes the same point: no proven screening test or prevention strategy exists for the general population, which is why noticing persistent lymphoma symptoms matters more than trying to prevent the disease.
How lymphoma is diagnosed
This is the part patients most often misunderstand, so it is worth stating plainly: blood tests support the assessment of lymphoma, but they never establish it. Only a tissue sample examined by a pathologist does that. Most people reach that point after a doctor has ordered a complete blood count panel.
What blood tests can and cannot show about lymphoma symptoms
The blood count cannot diagnose lymphoma, and a fully normal result does not rule it out — many people with early disease have entirely normal counts. What it does is flag consequences and prompt further questions.
- The panel reports hemoglobin, which may fall if the marrow is involved or if inflammation is prolonged.
- The same sample gives the platelet count, sometimes reduced when the marrow is crowded.
- The differential lists the lymphocyte count, which may be high, low or entirely unremarkable.
- Oncologists also measure an enzyme called lactate dehydrogenase; a raised value suggests a higher tumor burden and feeds into prognostic scoring.
- Some workups include the erythrocyte sedimentation rate, an inflammation marker used in Hodgkin lymphoma staging.
- Before treatment starts, teams check kidney and liver panels and uric acid, because rapidly dying tumor cells flood the bloodstream with breakdown products.
Every one of these findings has dozens of benign explanations: a raised inflammation marker after a chest infection is far more common than cancer, and a low hemoglobin value much more often reflects iron deficiency anemia. That is why results are read alongside the examination and the imaging, never alone.
The lymph node biopsy, which is what confirms it
A pathologist needs enough intact tissue to see how the cells are arranged, not just what they look like individually. An excisional biopsy, in which a whole node is removed under local or general anesthetic, remains the preferred approach when lymphoma is suspected. A core needle biopsy may be used for nodes that are hard to reach, though it sometimes yields too little architecture and has to be repeated. Fine needle aspiration, which draws out loose cells, is rarely sufficient alone. The sample then undergoes immunohistochemistry and often molecular testing — the step that names the subtype, which in turn dictates the treatment plan.
Imaging and staging
Once the diagnosis is made, a PET-CT scan maps which node groups and organs are involved. Most centers use a four-stage system based on how many node regions are affected, whether both sides of the diaphragm are involved, and whether organs outside the lymphatic system are reached. Stage is then combined with age, blood results and fitness in prognostic scores that guide treatment intensity.
Treatment options today
Lymphoma is among the most treatable cancers, and several subtypes are routinely cured. Treatment is chosen by subtype, stage, pace and overall health, so two patients with the same label can receive very different plans.
Watchful waiting
For slow-growing subtypes such as follicular lymphoma found before any lymphoma symptoms appear, starting treatment immediately does not extend life. Active monitoring with scheduled examinations, blood tests and scans is a deliberate strategy, not neglect, and treatment begins when the disease progresses.
Chemotherapy, antibody therapy and radiation
Combination chemotherapy remains the backbone of first-line care. For B-cell lymphomas it is usually paired with an antibody targeting a protein on the B-cell surface, an approach that markedly improved outcomes when it entered practice. Radiation is added for localized or bulky disease. Most regimens run in cycles over several months.
CAR-T cell therapy
CAR-T therapy re-engineers the patient’s own T cells: they are collected from the blood, modified in a laboratory so they recognize a marker on the lymphoma cells, multiplied, then infused back. It is used mainly for aggressive B-cell lymphoma that has returned or resisted earlier lines. The process takes weeks, requires a specialized center, and carries two distinctive risks — cytokine release syndrome, an intense immune reaction, and temporary neurological effects. Both are now well recognized and actively managed.
Bispecific antibodies
Bispecific antibodies are laboratory-made proteins with two grips: one holds the lymphoma cell, the other holds a T cell, bringing them together so the immune cell can attack. Unlike CAR-T they come off the shelf, with no personalized product to manufacture, which suits patients who cannot wait or are not candidates for cell therapy. Several are now approved for relapsed B-cell lymphoma.
Stem cell transplantation
High-dose chemotherapy followed by a transplant of blood-forming stem cells — taken either from the patient beforehand or from a matched donor — is still used in selected relapsed cases, though its role has narrowed as cell and antibody therapies have expanded.
Living with lymphoma and what follow-up looks like
After treatment ends, follow-up means examinations and blood work every few months at first, spacing out over the years, with imaging when something changes. Two issues deserve attention. Some chemotherapy agents and chest radiation carry long-term risks to the heart, lungs, thyroid and fertility, so survivorship plans include specific monitoring rather than generic checkups. And fatigue often outlasts treatment by months, responding better to graded activity than to prolonged rest. Returning lymphoma symptoms between visits — a new lump, renewed night sweats — should be reported rather than saved for the next appointment.
Patients frequently ask how lymphoma differs from two other blood cancers. A cancer starting in the bone marrow that floods the bloodstream with abnormal white cells is called leukemia, and a cancer of the antibody-producing plasma cells is called multiple myeloma. All three share laboratory findings but differ in origin, presentation and treatment.
Latest scientific advances
Research has moved quickly in the last three years, particularly around immune-based treatments and blood-based monitoring. Here is what it found, and what it means in practice.
Comparing CAR-T and bispecific antibodies
A 2024 pooled analysis in Blood brought together sixteen studies of people whose aggressive B-cell lymphoma had returned after two or more previous treatments. CAR-T therapy produced complete responses — no detectable disease — in roughly half of patients, against roughly a third for bispecific antibodies, but with more frequent severe side effects.
What this means for you: neither approach is simply better. The trade-off being weighed is a higher chance of clearing the disease against a heavier burden of short-term complications, judged against your age, fitness and how quickly treatment is needed.
The order in which they are given may matter
A 2025 systematic review in The Lancet Haematology pooled thirty studies covering more than two thousand patients and asked a newer question: does the order change the result? The signal was that giving a bispecific antibody before CAR-T was linked to better subsequent CAR-T responses than the reverse. The authors were careful — the numbers behind that comparison were small and the studies were not randomized, meaning patients were not assigned by chance, so this is still preliminary and needs confirmation.
What this means for you: sequencing is an active research question, not settled practice, and a reasonable thing to raise with a lymphoma specialist if more than one option exists.
Real-world results hold up, and timing counts
Trials enroll relatively fit, carefully selected participants, so results in everyday practice can disappoint. A 2023 systematic review in Transplantation and Cellular Therapy gathered outcomes from thousands of patients given commercially available CAR-T products outside trials, and found effectiveness and safety broadly consistent with the original trials. A 2025 analysis in Blood Advances looked at vein-to-vein time — the gap between collecting a patient’s T cells and infusing the finished product — and linked waits of forty days or more to lower response rates and shorter survival.
What this means for you: published CAR-T figures are not confined to ideal trial conditions, and scheduling is not mere administrative detail, so it is fair to ask a center about its turnaround time.
Blood tests that read tumor DNA
Tumors shed fragments of their DNA into the bloodstream. A 2025 review in the Journal of Hematology and Oncology set out how measuring this circulating tumor DNA — a liquid biopsy — can genotype lymphoma without surgery, track whether treatment is working, and pick up traces of disease too small to see on a scan. In Hodgkin lymphoma, a 2024 study in the Journal of Clinical Oncology applied the technique to several hundred patients from German trial groups and identified three biological subtypes with different outlooks.
What this means for you: these tests are not yet routine, and none of them replaces the initial biopsy. Their likely first use is monitoring — a blood draw instead of another scan — and tailoring how intensively an individual is treated. Expect them through clinical trials first.
Glossary
| Term | Definition |
|---|---|
| Lymphocyte | A white blood cell that fights infection. B lymphocytes make antibodies; T lymphocytes attack infected or abnormal cells. Lymphoma starts in one of these cells. |
| Lymph node | A small bean-shaped filtering station along the lymphatic system where immune cells gather. Nodes swell when they are working hard, and also when disease collects inside them. |
| B symptoms | The trio of unexplained fever, drenching night sweats and significant unintentional weight loss. Their presence affects staging and treatment decisions. |
| Excisional biopsy | Surgical removal of a whole lymph node so a pathologist can examine both the cells and how they are arranged. It is the preferred way to confirm lymphoma. |
| Immunohistochemistry | A laboratory staining technique that identifies proteins on the surface of cells in a biopsy sample, allowing the exact lymphoma subtype to be named. |
| Lactate dehydrogenase (LDH) | An enzyme present in almost every cell. Blood levels rise when many cells are breaking down, so it is used as a rough marker of disease burden, not as a diagnostic test. |
| PET-CT scan | An imaging test combining a radioactive sugar tracer with a CT scan, showing both where active disease sits and its precise anatomy. It is the standard tool for staging. |
| CAR-T cell therapy | Chimeric antigen receptor T-cell therapy. The patient’s own T cells are collected, genetically modified to recognize lymphoma cells, grown in number and returned by infusion. |
| Bispecific antibody | An engineered protein that binds a lymphoma cell with one arm and a T cell with the other, bringing them together so the immune cell can destroy the cancer cell. |
| Circulating tumor DNA | Fragments of DNA shed by tumor cells into the blood. Measuring them is called a liquid biopsy and is being studied for monitoring rather than for initial diagnosis. |
Frequently asked questions
Can a blood test detect lymphoma?
Not on its own. A blood test can reveal changes that are consistent with lymphoma — a low hemoglobin level, an unusual lymphocyte count, a raised lactate dehydrogenase value — and those findings may prompt further investigation. But none of them is specific to lymphoma, and a completely normal blood panel does not exclude it. Many people with early-stage disease have normal counts throughout. The diagnosis is made by removing a lymph node or a piece of affected tissue and having a pathologist examine it under the microscope. Blood work then supports staging, prognosis and treatment monitoring.
Is lymphoma curable?
Many lymphomas are. Hodgkin lymphoma in particular is often cured, including at advanced stages, and several aggressive non-Hodgkin subtypes can be cured with first-line treatment. Slow-growing subtypes such as follicular lymphoma are frequently not curable in the strict sense, but they can be controlled for many years with periods of treatment and periods of observation, and people often live a normal lifespan with them. Because the outlook varies so much between subtypes, general survival figures are of limited use to any individual. The specific subtype and stage are the numbers that matter.
What did the earliest signs feel like for most people?
The most commonly described starting point is a painless lump, usually in the neck or above the collarbone, that was noticed by accident while washing or shaving and simply did not go away. Fatigue disproportionate to activity, night sweats requiring a change of sleepwear, and itching without a rash are also frequently reported in hindsight. Many people describe feeling well otherwise, which is part of why diagnosis is often delayed. Symptoms that build gradually over weeks and do not fit an infection are the pattern worth acting on.
Are lymphoma symptoms different in women?
The core features are the same across sexes: painless node swelling, fever, night sweats, weight loss, itching and fatigue. What differs is how easily they can be attributed to something else. Night sweats and fatigue overlap with perimenopause, thyroid conditions and iron deficiency, so they are more often explained away in women. Node swelling in the armpit may also be noticed first during breast self-examination or on a mammogram. The practical takeaway is the same either way: a node that persists beyond two to three weeks warrants examination.
Does lymphoma run in families?
Only weakly. Having a parent, sibling or child with lymphoma raises your relative risk somewhat, but the underlying chance is low, so the absolute increase stays small. Inherited single-gene causes are rare and are usually part of broader immune deficiency syndromes. Most lymphoma arises from genetic changes acquired during life in a single lymphocyte, not from inherited mutations. There is no genetic screening program for relatives of people with lymphoma, and no evidence that routine scanning of healthy family members helps.
How long does lymphoma treatment take?
It depends on the subtype and the plan. First-line combination chemotherapy for an aggressive lymphoma typically runs in cycles over four to six months, with hospital visits every two or three weeks. Localized Hodgkin lymphoma may need a shorter course plus a few weeks of radiation. CAR-T therapy involves several weeks of preparation and manufacturing, then a hospital stay of a couple of weeks around the infusion and close monitoring afterwards. Slow-growing lymphoma under active monitoring may involve no treatment at all for years, only scheduled reviews.
Sources
- National Cancer Institute — Lymphoma, Patient Version — NIH, 2025 — cancer.gov
- Mayo Clinic — Lymphoma: symptoms and causes — Mayo Foundation for Medical Education and Research, 2025 — mayoclinic.org
- MedlinePlus — Lymphoma — National Library of Medicine, 2025 — medlineplus.gov
- Hanzalova I, Matter M — Peripheral lymphadenopathy of unknown origin in adults: a diagnostic approach emphasizing the malignancy hypothesis — Swiss Medical Weekly, 2024 — doi.org/10.57187/s.3549
- Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ — CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis — Blood, 2024 — doi.org/10.1182/blood.2023023419
- Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, Brailovski E, Assouline S — Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis — The Lancet Haematology, 2025 — doi.org/10.1016/S2352-3026(25)00318-7
- Jacobson CA, Munoz J, Sun F, et al. — Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis — Transplantation and Cellular Therapy, 2023 — doi.org/10.1016/j.jtct.2023.10.017
- Locke FL, Siddiqi T, Jacobson CA, et al. — Impact of vein-to-vein time in patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel — Blood Advances, 2025 — doi.org/10.1182/bloodadvances.2024013656
- Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H, Wang X — Circulating tumor DNA in lymphoma: technologies and applications — Journal of Hematology and Oncology, 2025 — doi.org/10.1186/s13045-025-01673-7
- Heger JM, Mammadova L, Mattlener J, et al. — Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma — Journal of Clinical Oncology, 2024 — doi.org/10.1200/JCO.23.01867
Further reading
- C-reactive protein and what it says about inflammation
- Neutrophils and your infection defenses
- Albumin levels and what they reflect
- Creatinine and kidney function
- Total calcium in your blood panel
Understand your lab results with BloodSense
If a doctor has ordered blood work because of a swollen node, fatigue or night sweats, the report that comes back is rarely self-explanatory. BloodSense reads your results in plain language and shows how the pieces fit together — the complete blood count, the lymphocyte and platelet numbers, inflammation markers, and enzymes such as lactate dehydrogenase. It helps you understand what your values mean and which questions are worth raising at your next appointment. It does not diagnose lymphoma or any other condition, and it does not replace your doctor.
